

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## YUE DA INTERNATIONAL HOLDINGS LIMITED

悅達國際控股有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 629)**

### CHANGE OF DIRECTORS AND AUTHORISED REPRESENTATIVE

The Board announces that, with effect from 18 July 2025:

- i. Dr. Teng Songsong has been appointed as an executive director of the Company;
- ii. Mr. Wu Shengquan has resigned from his position as an executive director of the Company and ceased to be an Authorised Representative; and
- iii. Mr. Ji Hulin, an executive director of the Company has been appointed an Authorised Representative.

### RESIGNATION OF DIRECTOR

The board of directors (the “**Board**”) of Yue Da International Holdings Limited (the “**Company**”) hereby announces that, with effect from 18 July 2025, Mr. Wu Shengquan has tendered his resignation as an executive director of the Company due to the re-designation of roles within the ultimate beneficial owner of the Company and its subsidiaries. Mr. Wu Shengquan remains as the Chief Financial Officer of the Company.

Mr. Wu Shengquan has confirmed that he has no disagreement with the Board and there are no other matters that need to be brought to the attention of holders of securities of the Company in connection with his resignation as an executive director of the Company.

The Company would like to express its sincere gratitude to Mr. Wu Shengquan for his valuable contribution to the Board and the Company during his term of office.

### APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that, with effect from 18 July 2025, Teng Songsong (“**Dr. Teng**”) was appointed as an executive director of the Company.

Set out below are the biographical details of Dr. Teng.

Dr. Teng, aged 39, graduated from Nanjing Medical University with a master's degree in clinical medicine and Hannover Medical School in Germany with a doctorate degree in biomedical science. Dr. Teng worked in the Department of Orthopedics of the Shanghai First People's Hospital for over four years and has rich clinical medical experience. He was also a member of the Regenerative Medicine Translational Chemistry Group of the Reconstructive Surgery Committee of the Chinese Association of Rehabilitation Medicine and a member of the Sports Rehabilitation Group of the Sports Medicine Specialty Branch of the Shanghai Medical Association. He was sponsored by Shanghai Pujiang Talent Program (Class A) jointly established by Shanghai Municipal Human Resources and Social Security Bureau and Shanghai Municipal Science and Technology Commission to conduct research on abnormal skeletal development. Dr. Teng is currently a partner of 南通藍灣創業投資管理有限公司 (Nantong Blue Bay Venture Capital Management Co., Limited\*).

Save as disclosed above, as at the date of this announcement, Dr. Teng (i) does not have any relationship with any directors, senior management, or substantial or controlling shareholders of the Company; (ii) does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (iii) did not hold any other directorships in the last three years up to the date of this announcement in public companies, the securities of which are listed on any securities market in Hong Kong or overseas.

There is an appointment letter issued by the Company to Dr. Teng with no fixed terms. He will be subject to retirement by rotation and re-election at the Company's first general meeting after his appointment pursuant to the bye-laws of the Company. Dr. Teng is entitled to receive a remuneration of RMB100,000 per annum which is determined with reference to his experience and responsibilities with the Company, the prevailing market conditions and the terms of the remuneration policy of the Company.

Save as disclosed above, there are no other matters or information that need to be brought to the attention of shareholders of the Company or to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("**Listing Rules**") in relation to the aforesaid appointment.

The Board would like to express its warm welcome to Dr. Teng to the Board.

## **CHANGE OF AUTHORISED REPRESENTATIVE**

With effect from 18 July 2025, (i) Mr. Wu Shengquan ceased to be authorised representative of the Company under Rule 3.05 of the Listing Rules ("**Authorised Representative**"); and (ii) Mr. Ji Hulin, executive director of the Company was appointed as Authorised Representative of the Company.

By order of the Board  
**Yue Da International Holdings Limited**  
**Ji Hulin**  
*Chairman and Executive Director*

Hong Kong, 18 July 2025

*As at the date of this announcement, the Board comprises the following members: (a) as executive Directors, Mr. Ji Hulin, Mr. Xue Zhicheng, Mr. Pan Mingfeng and Dr. Teng Songsong (b) as non-executive Directors, Mr. Li Biao and Mr. Hu Huaimin; and (c) as independent non-executive Directors, Dr. Liu Yongping, Mr. Cheung Ting Kee and Ms. Zhang Yan.*

*If there is any inconsistency in this announcement between the Chinese and English versions, the English version shall prevail.*

*\* English translation for identification purpose only.*